0.40
+0.0448(+12.67%)
Currency In USD
| Previous Close | 0.35 |
| Open | 0.35 |
| Day High | 0.41 |
| Day Low | 0.34 |
| 52-Week High | 3.09 |
| 52-Week Low | 0.34 |
| Volume | 360,961 |
| Average Volume | 8.67M |
| Market Cap | 2.05M |
| PE | -0.09 |
| EPS | -4.51 |
| Moving Average 50 Days | 0.62 |
| Moving Average 200 Days | 1.16 |
| Change | 0.04 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $3.93 as of February 07, 2026 at a share price of $0.398. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 1 year ago, it would be worth $147.56 as of February 07, 2026 at a share price of $0.398.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
GlobeNewswire Inc.
Jan 28, 2026 1:30 PM GMT
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical dat
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
GlobeNewswire Inc.
Jan 09, 2026 1:45 PM GMT
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) --
Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
GlobeNewswire Inc.
Dec 30, 2025 1:30 PM GMT
With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly granted patent further strengthens the Company’s strategic position in a multi-billion-do